1. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Clinical and experimental
studies on condyloma acuminate. 2000; 22 (5): 487–90.
2. Stefanaki C, Hadjivassiliou M, Katzouranis I et al. Prognostic factors
for the response to treatment in males with genital warts. J Eur Acad
Dermatol Venereol. 2009 Apr 30. [Epub ahead of print].
3. Fleischer AB, Parrish CA, Glenn R, Feldman SR. Condylomata acuminata
(genital warts): patient demographics and treating physicians.
Sex Transm Dis 2001; 28: 643–7.
4. Brown DR, Schroeder JM, Bryan JT et al. Detection of multiple human
papillomavirus types in Condylomata acuminata lesions from otherwise
healthy and immunosuppressed. J Clin Microbiol 1999; 37:
3316–22.
5. Coleman N, Birley HD, Renton AM et al. Immunological events in
regressing genital warts. Am J Clin Pathol 1994; 102: 768–74.
6. Chuang TY, Brashear R. Genital Warts. Emedicine. Dermatology
Chapter. http://www.emedicine.com/derm/topic454.htm (accessed
February 10, 2006).
7. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician
2004; 70: 2335–42.
8. Lombard I, Vincent-Salomon A, Validire P et al. Human papillomavirus
genotype as a major determinant of the course of cervical cancer.
J Clin Oncol 1998; 16: 2613–9.
9. Scheinfeld N, Lehman DS. An evidence-based review of medical and
surgical treatments of genital warts Dermatology Online Journal 2006;
12 (3): 5.
10. Buck H Jr. Warts (genital). Clin Evid (Online). 2007; pii: 1602.
11. Baken LA, Koutsky LA, Kuypers J et al. Genital human papillomavirus
infection among male and female sex partners: prevalence
and type-specific concordance. J Infect Dis 1995; 171: 429–32.
12. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal
papillomavirus infection in young women. N Engl J Med 1998; 338:
423–8.
13. Kirnbauer R, Lenz P, Okun MM. Human Papillomavirus. In: Bolognia
J, Jorizzo J, Rapini R, eds. Dermatology. 1st ed. London: Mosby, 2003;
1217–33.
14. Scheinfeld NS, Lehman D. Condyloma with lichen nitidus. Skinmed
2005; 4 (3): 177–8.
15. Krough G, Longstaff E. Podophyllin office therapy against condyloma
should be abandoned. Sex Transm Infect 2001; 77: 409–12.
16. Fox PA, Tung MY. Human papillomavirus: burden of illness and
treatment cost considerations. Am J Clin Dermatol 2005; 6 (6):
365–81.
17. Takeki Saitoh, Kouji Kuramochi, Takahiko Imai et al. Podophyllotoxin
directly binds a hinge domain in E2 of HPV and inhibits an E2/E7
interaction in vitro. Bioorgan Med Chem 2008; 16 (10): 5815–25.
18. Nan Fang Yi Ke Da Xue Xue Bao. Treatment of recurrent condyloma
acuminatum with solid lipid nanoparticle gel containing podophyllotoxin:
a randomized double-blinded, controlled clinical trial. 2007;
27 (5): 657–9.
19. Yan J, Chen SL, Wang HN, Wu TX. Meta-analysis of 5% imiquimod
and 0,5% podophyllotoxin in the treatment of condylomata acuminate.
Dermatology 2006; 213 (3): 218–23.